Sfoglia per AUTORE
BEANO A
Collezione ASL Città di Torino

  

Items : 10

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Nov 10;41(32):4976-4981. doi: 10.1200/JCO.23.00790. Epub 2023 Sep 25.

2023
ASL Città di Torino
AOU Città della Salute di Torino

Guarneri V; D'Amico R; Balduzzi S; Vicini R; Dieci MV; Miglietta F; Beano A; Rimanti A; Giotta F; Turletti A; Garrone O; Schirone A; Musolino A; Anselmi E; Aieta M; Gebbia V; Sarti S; Minichillo S; Piacentini F; Conte P; Bisagni G;

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study. in Cancers / Cancers (Basel). 2023 Dec 25;16(1):117. doi: 10.3390/cancers16010117.

2023
AOU Città della Salute di Torino
ASL Città di Torino

Mustacchi G; Zambelli A; Verusio C; Turletti A; Tonini G; Tagliaferri P; Tinari N; Sarobba G; Spazzapan S; Romagnoli E; Ricciardi G; Riccardi F; Putzu C; Montemurro F; Michelotti A; Mattioli R; Marchetti P; Livi L; Latini L; Giovanardi F; Giotta F; Garrone O; Gennari A; Giordano M; Gamucci T; Forcignanò R; Ferraù F; Foladore S; Crinò L; et alii...

Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial in Journal of Clinical Oncology

2023
AOU Città della Salute di Torino
ASL Città di Torino

Conte PF; Bisagni G; Piacentini F; Sarti S; Minichillo S; Anselmi E; Aieta M; Gebbia V; Schirone A; Musolino A; Garrone O; Beano A; Rimanti A; Giotta F; Turletti A; Dieci MV; Vicini R; Balduzzi S; D'Amico R; Guarneri V;

Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study in Cancer Research

2020
ASL Città di Torino

Cazzaniga ME; Pronzato P; Arpino G; D'Alonzo A; Riemma M; Natoli C; Milani A; Blasi L; Turletti A; Giordano M; Biganzoli L; Garrone O; Diodati L; Riccardi F; Marchetti P; Bernardo A; Livi L; Fabi A; Beano A; Mustacchi G;

Nab-paclitaxel in clinical practice: Data from the MANTEL study in Annals of Oncology

2017
ASL Asti
ASL Città di Torino
ASL Torino 4
AOU Città della Salute di Torino

Vanella P; Garrone O; Saggia C; Bergnolo P; Beano A; Airoldi M; Turletti A; Castiglione F; Manzin E; Denaro N; De Conciliis E; Vandone AM; Donadio M; Miraglio E; Merlano MC; Cursano MC; De Angelis C; Giarratano T; Cazzaniga M; La Verde N; Milani A; Collová E; Coltelli L; D'Onofrio L; Bertolini I; Guarneri V; Riva F; Mustacchi G; Giordano M; et alii...

Nab-paclitaxel in clinical practice: data from the MANTEL study in Annals of oncology : official journal of the European Society for Medical Oncology

2017
ASL Città di Torino
ASL Torino 4

Vanella P; Garrone O; Saggia C; Bergnolo P; Beano A; Airoldi M; Turletti A; Castiglione F; Manzin E; Denaro N; de Conciliis E; Vandone AM; Donadio M; Miraglio E; Merlano MC;

The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Romagnoli E; Montemurro F; De Laurentiis M; Riccardi F; Turletti A; Beano A; De Angelis C; Graziano V; Livi L; Del Mastro L; Biganzoli L; Garrone O; De Placido S; Marchetti P; Pronzato P;

Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts) in Journal of Clinical Oncology

2017
ASL Città di Torino

Cazzaniga ME; Mustacchi G; Romagnoli E; Montemurro F; Caporello P; De Laurentiis M; Riccardi F; Turletti A; De Angelis C; Graziano V; Livi L; Del Mastro L; Beano A; Garrone O; Biganzoli L; Pronzato P; De Placido S;

Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Giordano M; Garrone O; Beano A; Del Mastro L; Livi L; Iezzi L; Michelotti A; Turletti A; Riccardi F; De Laurentiis M; Marchetti P; Biganzoli L; Montemurro F; Romagnoli E; De Placido S; Pronzato P;

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study in Journal of Cancer Research and Clinical Oncology

2016
ASL Città di Torino

Arpino G; Michelotti A; Truini M; Montemurro F; Russo S; Palumbo R; Zamagni C; Latorre A; Bruzzese D; Riccardi F; De Laurentiis M; Beano A; Biganzoli L; Zaniboni A; Laudadio L; Malagoli M; Bilancia D; Schettini F; Giuliano M; Cazzaniga ME; De Placido S;